Jin Li
Research Subjects
Research Interests
Jin Li has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Eliot L. Gardner
Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA
2 shared publicationsHua-Jin Dong
Beijing Institute of Pharmacology and toxicology, 27 Taiping Road, Beijing 100850, China
2 shared publications- Ri-Fang Yang
Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China
2 shared publications Rui Song
Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA
2 shared publications- Ruibin Su
State Key Laboratory of National Security Specially Needed Medicines, Beijing, China
2 shared publications Wei Lu
Beijing Institute of Pharmacology and toxicology, 27 Taiping Road, Beijing 100850, China
2 shared publications
Latest Publications
- 1 September 2013
- Published by Elsevier in Neuropharmacology
- Vol. 72, 82-87
Dopamine D3 receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice
- 1 September 2013
- Published by Elsevier in Neuropharmacology
- Vol. 72, 82-87
Dopamine D3 receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice
- 20 April 2011
- Published by Wiley in Addiction Biology
- Vol. 17 (2) , 259-273
YQA14: a novel dopamine D3receptor antagonist that inhibits cocaine self‐administration in rats and mice, but not in D3receptor‐knockout mice
The dopamine (DA) D3 receptor is posited to be importantly involved in drug reward and addiction, and D3 receptor antagonists have shown extraordinary promise as potential anti‐addiction pharmacotherapeutic agents in animal models of drug addiction. SB‐277011A is the best characterized D3 receptor antagonist in such models. However, the potential use of SB‐277011A in humans is precluded by pharmacokinetic and toxicity problems. We here report a novel D3 receptor antagonist YQA14 that shows similar pharmacological properties as SB‐277011A.In vitroreceptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors withKi‐High(0.68 × 10−4 nM) andKi‐Low(2.11 nM), and displays > 150‐fold selectivity for D3 over D2 receptors and > 1000‐fold selectivity for D3 over other DA receptors. Systemic administration of YQA14 (6.25–25 mg/kg) or SB‐277011A (12.5–25 mg/kg) significantly and dose‐dependently reduced intravenous cocaine self‐administration under both low fixed‐ratio and progressive‐ratio reinforcement conditions in rats, while failing to alter oral sucrose self‐administration and locomotor activity, suggesting a selective inhibition of drug reward. However, when the drug dose was increased to 50 mg/kg, YQA14 and SB‐277011A significantly inhibited basal and cocaine‐enhanced locomotion in rats. Finally, both D3 antagonists dose‐dependently inhibited intravenous cocaine self‐administration in wild‐type mice, but not in D3 receptor‐knockout mice, suggesting that their action is mediated by D3 receptor blockade. These findings suggest that YQA14 has a similar anti‐addiction profile as SB‐277011A, and deserves further study and development.
- 20 April 2011
- Published by Wiley in Addiction Biology
- Vol. 17 (2) , 259-273
YQA14: a novel dopamine D3receptor antagonist that inhibits cocaine self‐administration in rats and mice, but not in D3receptor‐knockout mice
The dopamine (DA) D3 receptor is posited to be importantly involved in drug reward and addiction, and D3 receptor antagonists have shown extraordinary promise as potential anti‐addiction pharmacotherapeutic agents in animal models of drug addiction. SB‐277011A is the best characterized D3 receptor antagonist in such models. However, the potential use of SB‐277011A in humans is precluded by pharmacokinetic and toxicity problems. We here report a novel D3 receptor antagonist YQA14 that shows similar pharmacological properties as SB‐277011A.In vitroreceptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors withKi‐High(0.68 × 10−4 nM) andKi‐Low(2.11 nM), and displays > 150‐fold selectivity for D3 over D2 receptors and > 1000‐fold selectivity for D3 over other DA receptors. Systemic administration of YQA14 (6.25–25 mg/kg) or SB‐277011A (12.5–25 mg/kg) significantly and dose‐dependently reduced intravenous cocaine self‐administration under both low fixed‐ratio and progressive‐ratio reinforcement conditions in rats, while failing to alter oral sucrose self‐administration and locomotor activity, suggesting a selective inhibition of drug reward. However, when the drug dose was increased to 50 mg/kg, YQA14 and SB‐277011A significantly inhibited basal and cocaine‐enhanced locomotion in rats. Finally, both D3 antagonists dose‐dependently inhibited intravenous cocaine self‐administration in wild‐type mice, but not in D3 receptor‐knockout mice, suggesting that their action is mediated by D3 receptor blockade. These findings suggest that YQA14 has a similar anti‐addiction profile as SB‐277011A, and deserves further study and development.
- 31 December 2010
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 97 (2) , 256-261
Agmatine inhibits morphine-induced memory impairment in the mouse step-down inhibitory avoidance task
- 31 December 2010
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 97 (2) , 256-261
Agmatine inhibits morphine-induced memory impairment in the mouse step-down inhibitory avoidance task
- 1 August 2010
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 96 (2) , 125-129
Effect of agmatine on long-term potentiation in morphine-treated rats
- 1 August 2010
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 96 (2) , 125-129
Effect of agmatine on long-term potentiation in morphine-treated rats
- Open Access
Synthesis and Analgesic Activity Evaluation of Some Agmatine Derivatives
A series of N,N’-disubstituted-2-nitroethene-1,1-diamine and N,N’-disubstituted- N’’-cyanoguanidine derivatives were prepared and evaluated for in vivo analgesic activity. The blood brain barrier (BBB) VolSurf model was used to predict the BBB permeation profiles of our synthesized compounds. Some compounds show both remarkable analgesic activity and good BBB permeation profiles, and these compounds might be developed for treatment of opioid tolerance and dependence.
Open AccessSynthesis and Analgesic Activity Evaluation of Some Agmatine Derivatives
A series of N,N’-disubstituted-2-nitroethene-1,1-diamine and N,N’-disubstituted- N’’-cyanoguanidine derivatives were prepared and evaluated for in vivo analgesic activity. The blood brain barrier (BBB) VolSurf model was used to predict the BBB permeation profiles of our synthesized compounds. Some compounds show both remarkable analgesic activity and good BBB permeation profiles, and these compounds might be developed for treatment of opioid tolerance and dependence.